SK-N-SH: Human Neuroblastoma Cell Line (ATCC HTB-11)

SK1980-529

Description

SK-N-SH is a neuroblastoma cell line that displays epithelial morphology and grows in adherent culture. Treatment with all-trans-retinoic acid causes these cells to differentiate and adopt a neuronal phenotype, characterized by extensive neurite outgrowth. This makes them particularly useful for delineating signaling pathways involved in neuronal differentiation. In addition, the SK-N-SH cells are known to form tumors in immunocompromised mice.

Source

This cell line was established in 1970 from metastatic cells found in the bone marrow aspirate of a four-year-old female of unknown ethnicity.

Inventors

  • June L. Biedler, PhD, former Chairman, Cell Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering
  • Barbara A. Spengler, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Biedler JL et al. (1973) Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Research 33: 2643-2652 (PubMed ID: 4748425)
  • Helson L et al. (1975) Human neuroblastoma in nude mice. Cancer Research 35: 2594-2599 (PubMed ID: 167965)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

For internal research purposes by a commercial entity: Utilize MSK’s Express License, available here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.

To proceed, please download this contract, fill in all relevant fields, and email a scanned version to Alexandra Buga at bugaa@mskcc.org.  Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.

For licensing requests for a commercial purpose:  Contact Alexandra Buga, MS, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org.

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org

Stage of Development

Ready to use

Indications